-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 10, Laikai Pharmaceuticals announced that its clinical phase I/II trial application for a combined treatment regimen for patients with anti-PD-1/PD-L1-resistant specific solid tumors has been approved by the CDE
This "Phase I/II dose escalation and efficacy/safety study of auresertib+sintilimab+chemotherapy in patients with anti-PD-1/PD-L1-resistant specific solid tumors" was conducted by the associate hospital of Peking University Cancer Hospital.
The goal of this study is to partially evaluate the safety of the above-mentioned three drugs in combination, determine the recommended dose for the Phase II study, and evaluate the clinical efficacy and safety of the combination therapy in the Phase II study
Note: The original text has been deleted